Mitchel S. Berger, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
berger_mitchel

Chair, Department of Neurological Surgery, and Director, Brain Tumor Research Center, UCSF
Berthold and Belle N. Guggenhime Professorship, UCSF

bergerm@neurosurg.ucsf.edu

Phone: (415) 353-3933 (academic); (415) 353-7500 (clinic)
Box 0112, UCSF
San Francisco, CA 94143-0112

View on UCSF Profiles


Additional Websites


Education

Harvard University, Cambridge, MA, A.B., 1975, Social Psychology
University of Miami, Miami, FL, M.D., 1979, Medicine
University of California, San Francisco, CA (UCSF), Dept. of Neurological Surgery, Brain Tumor Research Center (BTRC) Research Fellow 1983 - 1984 Neurosurgery
UCSF, BTRC, Neuro-Oncology Service, Clinical Fellow, 7/85 - 12/85, Neurosurgery
Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Neurosurgery Fellow, 1/86 - 6/86, Neurosurgery


Professional Experience

  • 1980 - 1982
    Residency, Dept. of Neurological Surgery, University of California, San Francisco, CA (UCSF)
  • 1986 - 1992
    Asst. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1990 - 1992
    Assoc. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1995 - 1992
    American Cancer Society Prof. of Clinical Oncology, University of Washington, Seattle, WA
  • 1996 - 1992
    Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1997 - present
    Professor and Chair, Dept. of Neurological Surgery, UCSF, San Francisco, CA
  • 1997 - present
    Director, Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF

Honors & Awards

  • 1997-Present
    Joint Section on Tumors Advisory Council, American Association of Neurological Surgeons and Congress of Neurological Surgeons
  • 1997-1999
    Vice-President, Congress of Neurological Surgeons; President, Society for Neuro-Oncology
  • 2002-Present
    America’s Top Doctors, peer-nominated referral index from Castle Connolly
  • 2006
    Tumor Section, 2006 Ronald L. Bittner Lecturer; 2006 Farber Award Winner
  • 2007–Present
    Board of Directors of the American Association of Neurological Surgeons
  • 2007–Present
    Member of the American Board of Neurological Surgeons
  • 2010
    Vice-President, American Association of Neurological Surgeons
  • 2011
    President Elect, American Association of Neurological Surgeons

Selected Publications

  1. Berger MS, Bruce JN, Chen TC, Zadeh G. Introduction: Glioblastoma: an update on pathophysiology and management strategies. Neurosurg Focus. 2014 Dec; 37(6):Introduction.
    View on PubMed
  2. Hervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery. 2014 Nov; 75(5):491-9.
    View on PubMed
  3. Rolston JD, Zygourakis CC, Han SJ, Lau CY, Berger MS, Parsa AT. Medical errors in neurosurgery. Surg Neurol Int. 2014; 5(Suppl 10):S435-40.
    View on PubMed
  4. Saigal R, Berger MS. The Long-term Effects of Repetitive Mild Head Injuries in Sports. Neurosurgery. 2014 Oct; 75 Suppl 4:S149-55.
    View on PubMed
  5. Hervey-Jumper SL, Breshears J, Berger MS. Gelfoam scaffold for vein prolapse during brain tumor surgery. World Neurosurg. 2014 Nov; 82(5):912.e11-3.
    View on PubMed
  6. Foret MR, Sandstrom RS, Rhodes CT, Wang Y, Berger MS, Lin CH. Molecular targets of chromatin repressive mark H3K9me3 in primate progenitor cells within adult neurogenic niches. Front Genet. 2014; 5:252.
    View on PubMed
  7. Saigal R, Batjer HH, Ellenbogen RG, Berger MS. Return to play for neurosurgical patients. World Neurosurg. 2014 Sep-Oct; 82(3-4):485-91.
    View on PubMed
  8. Sandstrom RS, Foret MR, Grow DA, Haugen E, Rhodes CT, Cardona AE, Phelix CF, Wang Y, Berger MS, Lin CH. Epigenetic Regulation by Chromatin Activation Mark H3K4me3 in Primate Progenitor Cells within Adult Neurogenic Niche. Sci Rep. 2014; 4:5371.
    View on PubMed
  9. Caverzasi E, Papinutto N, Amirbekian B, Berger MS, Henry RG. Q-ball of inferior fronto-occipital fasciculus and beyond. PLoS One. 2014; 9(6):e100274.
    View on PubMed
  10. Krieg SM, Tarapore PE, Picht T, Tanigawa N, Houde J, Sollmann N, Meyer B, Vajkoczy P, Berger MS, Ringel F, Nagarajan S. Optimal timing of pulse onset for language mapping with navigated repetitive transcranial magnetic stimulation. Neuroimage. 2014 Oct; 100:219-36.
    View on PubMed
  11. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel-Passow JE. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014 Jul; 46(7):731-5.
    View on PubMed
  12. Mandelli ML, Berger MS, Bucci M, Berman JI, Amirbekian B, Henry RG. Quantifying accuracy and precision of diffusion MR tractography of the corticospinal tract in brain tumors. J Neurosurg. 2014 Aug; 121(2):349-58.
    View on PubMed
  13. Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol. 2014 Apr; 16(4):284.
    View on PubMed
  14. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62.
    View on PubMed
  15. Safaee M, Oh MC, Mummaneni PV, Weinstein PR, Ames CP, Chou D, Berger MS, Parsa AT, Gupta N. Surgical outcomes in spinal cord ependymomas and the importance of extent of resection in children and young adults. J Neurosurg Pediatr. 2014 Apr; 13(4):393-9.
    View on PubMed
  16. Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond). 2014 Feb 4.
    View on PubMed
  17. Berger MS. Editorial: The fluorescein-guided technique. Neurosurg Focus. 2014 Feb; 36(2):E6.
    View on PubMed
  18. Berger MS. Editorial: Use of 5-aminolevulinic acid helps see the way beyond MRI. Neurosurg Focus. 2014 Feb; 36(2):E4.
    View on PubMed
  19. Safaee M, Sun MZ, Oh T, Aghi MK, Berger MS, McDermott MW, Parsa AT, Bloch O. Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. Clin Neurol Neurosurg. 2014 Apr; 119:116-20.
    View on PubMed
  20. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJ, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10; 343(6167):189-93.
    View on PubMed

Go to UCSF Profiles, powered by CTSI